Nyxoah Touts Genio U.S. Launch Traction, Reimbursement Stability at Investor Day

Nyxoah said its U.S. Genio launch is gaining traction, citing 262 trained surgeons, 123 ordering customers, and 427 patients in prior authorization.

Management also said early launched accounts reached a 15% market share in their first six months.

Reimbursement remains stable, with company officials and reimbursement experts saying recent CMS code changes do not affect coverage.

They noted that most U.S. patients are commercially insured and that prior authorization approvals have been running at a 100% rate so far.

The company outlined both a clinical expansion plan and a path to profitability, including a possible U.S. label update for complete concentric collapse in early 2027 pending trial data.

Nyxoah reiterated 2026 revenue guidance of EUR 36 million to EUR 40 million and said it has a preliminary cash balance of EUR 98 million.

Nyxoah used its investor day presentation to outline early U.S. launch progress for its Genio hypoglossal nerve stimulation system, address reimbursement questions and describe its path toward profitability.

Chief Executive Officer Olivier Taelman said there is “a lot of excitement inside of the company” following the release of preliminary quarterly results, and said the company remains focused on U.S. commercialization, clinical expansion and long-term innovation in obstructive sleep apnea treatment.